American Orthopedic Spine Surgeon Successfully Treated for Autoimmune Arthritis with His Own Stem Cells

News provided by

Jan 26, 2011, 04:41 ET

GERMANTOWN, Md., Jan. 26, 2011 /PRNewswire/ -- RNL BIO CO., LTD, a leading biopharmaceutical company specialized in adult stem cell therapeutics, announced on January 21, 2011 another successful patient report utilizing stem cell therapy on a leading US orthopedic spine surgeon who suffered from Autoimmune Arthritis.

Dr. Stanley Jones, the surgeon and patient, reports that he had a sudden onset of acute pain in his wrist in September 2009; shortly thereafter the patient experiences pain in his knees as well. Dr. Jones saw a rheumatologist who diagnosed him with Autoimmune Arthritis. He was placed on Cortisone, a steroid hormone, to suppress immune response and alleviate pain. Unfortunately Dr. Jones suffered complications from the Cortisone including chest pain and Candidiasis which were unbearable. His condition deteriorated and his ability to perform routine activities of daily living or his profession was impacted.

After visiting many physicians and talking with experts in the field, Dr. Jones was introduced to RNL Bio's stem cell therapy. After a workup, he received stem cell infusions in Kyoto, Japan in May 2010. Post infusion, he began to notice improvement and by the 5 month, he had a complete recovery and was able to resume sports as well as operating! In addition, he no longer needed any medications including Cortisone or Methotrexate. Dr. Jones' rheumatologist in Houston saw Dr. Jones post infusion and said, "It is amazing that Dr. Jones was able to experience improvement from cutting-edge medical technology."

Other patients treated by the company have had very successful results as reported by RNL BIO Co., Ltd in 2009, an American artist, John Cullison's stem cell treatment for Rheumatoid Arthritis, and in September 2010, Japanese Yosida's treatment for psoriasis.

About RNL BIO CO., LTD.

RNL BIO is a premier biotechnology company focused on the research and development of adult derived stem cell therapies. RNL has two therapies in Phase II clinical trials for Buerger's Disease as well as Osteoarthritis and one phase I trial for spinal cord injury. RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.

Video Interview Link:

http://www.youtube.com/watch?v=xzDElPr9gRo